biotech / news / / The Manila Times
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response.
EVX-01 personalized vaccine triggered tumor-specific immune responses in 86% of selected targets.
KEY POINTS
- This 86% success rate is significantly higher than previously reported for other vaccine target identification methods.
- Durable vaccine-specific immune responses persisted for two years after EVX-01 administration in phase 2 data.
- AI-Immunology™ prediction scores positively correlate with the magnitude of measured immune responses.
- The trial in advanced melanoma showed a 75% Objective Response Rate, with three-year data expected in late 2026.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →